云南省艾滋病重点人群丙型肝炎检测结果分析

Hepatitis C testing results among HIV key populations in Yunnan Province

目的 了解和掌握云南省艾滋病7类重点人群丙型肝炎(简称丙肝)流行水平,评估云南省丙肝检测策略,为进一步制订和优化防治措施提供依据。方法 收集汇总2023年云南省艾滋病7类重点人群的丙肝检测报表和2023年“丙型肝炎综合防治信息年度报表”,分析不同人群、不同地区的抗体阳性率和核酸阳性率。结果 2023年1-12月云南省艾滋病7类重点人群累计检测HCV抗体240 190人,HCV抗体阳性率为5.48%(13 151/240 190),核酸阳性率为62.96%(4 731/7 514);其中社区药物维持治疗门诊就诊者、强制/劳教戒毒人员、HIV感染者、羁押人员、HIV感染者配偶或性伴、暗娼、MSM的HCV抗体阳性率依次为:19.50%、12.25%、9.54%、2.25%、1.19%、0.35%和0.25%。结论 云南省艾滋病7类重点人群丙肝抗体和核酸阳性率均较高,应依托艾滋病防治机制和平台持续推进“多病共检、多病共防”等策略,提高丙肝发现率和抗病毒治疗率。

Objective To understand the prevalence of hepatitis C virus(HCV)among the seven key populations of HIV/AIDS in Yunnan Province,and to evaluate the HCV testing strategies in order to provide evidence for further development and optimization of prevention and control measures.Methods The HCV testing reports of the seven key populations of HIV/AIDS in Yunnan Province in 2023 were collected and summarized,together with the Annual Report on Comprehensive Prevention and Control of Hepatitis C in 2023.The antibody positivity rate and nucleic acid positivity rate were analyzed among different populations and in different regions.Results From January to December 2023,a total of 240190 individuals were tested for HCV antibodies among the seven key HIV/AIDS populations in Yunnan Province.The antibody positivity rate was 5.48%(13151/240190),and the nucleic acid positivity rate was 62.96%(4731/7514).Among the different populations,the antibody positivity rates of community-based drug maintenance outpatients,compulsory/re-education drug users,HIV-infected individuals,detainees,spouses or sexual partners of HIV-infected individuals,sex workers,and men who have sex with men(MSM)were 19.50%,12.25%,9.54%,2.25%,1.19%,0.35%,and 0.25%,respectively.Conclusions The antibody and nucleic acid positivity rates of HCV among the seven key populations of HIV/AIDS in Yunnan Province are relatively high.It is recommended to further promote strategies such as"multiple disease co-testing,multiple disease co-prevention"based on the HIV/AIDS prevention and control mechanism and platform,in order to improve the detection rate and the rate of antiviral treatment for HCV.